Impact of prior bendamustine exposure on bispecific antibody outcomes in relapsed/refractory follicular lymphoma.

Gloria Iacoboni; Emil Ramsø Kyvsgaard; Víctor Navarro Garcés; David A. Russler-Germain; Katharine L. Lewis; Alejandro Martín García-Sancho; Itziar Carro; Philip A. Thompson; Dylan Therwhanger; David Quintela; Matthew Ku; Pilar González Gómez; Evelyn Valencia; Gala Vega; Ana Jiménez Ubieto; Mariana Beatriz Bastos-Oreiro; Angel Serna; Simon Husby; Beatriz De La Cruz; Jing Luan; Sergi Camarillas; Lucía Medina; A. Cabero; Raúl Córdoba; Miguel Canales; Juan-Manuel Sancho; F. Bosch; Anna M. Sureda; Stephen Schuster; Calvin Cheah; Martin Hutchings; P. Barba; Pau Abrisqueta

doi:10.1182/bloodadvances.2025018546

← 뒤로

Impact of prior bendamustine exposure on bispecific antibody outcomes in relapsed/refractory follicular lymphoma.

2/5 보강

Blood advances 📖 저널 OA 99.1% 2021~2026 2026 Vol.10(6) p. 1947-1951 cited 1 OA Lymphoma Diagnosis and Treatment

OpenAlex 토픽 · Lymphoma Diagnosis and Treatment Cutaneous lymphoproliferative disorders research Chronic Lymphocytic Leukemia Research

Iacoboni G, Kyvsgaard ER, Navarro Garcés V, Russler-Germain DA, Lewis K, Martín García-Sancho A

📖 무료 전문 🟢 PMC 전문 PMC12995481 🔓 OA PDF unpaywall · cc-by-nc-nd

PubMed ↗ DOI ↗ BibTeX ↓ RIS ↓

이 논문을 인용하기

↓ .bib ↓ .ris

APA Gloria Iacoboni, Emil Ramsø Kyvsgaard, et al. (2026). Impact of prior bendamustine exposure on bispecific antibody outcomes in relapsed/refractory follicular lymphoma.. Blood advances, 10(6), 1947-1951. https://doi.org/10.1182/bloodadvances.2025018546

MLA Gloria Iacoboni, et al.. "Impact of prior bendamustine exposure on bispecific antibody outcomes in relapsed/refractory follicular lymphoma.." Blood advances, vol. 10, no. 6, 2026, pp. 1947-1951.

PMID 41499758 ↗

DOI 10.1182/bloodadvances.2025018546

같은 제1저자의 인용 많은 논문 (1)

Selecting the best treatment approach and optimizing sequencing strategies in large B-cell lymphoma.
Hematology. American Society of Hematology. Education Program 2025